Publications by authors named "Jan J Molenaar"

55Publications

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.

EBioMedicine 2020 Sep 23;59:102971. Epub 2020 Aug 23.

Paediatric Tumour Biology, Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom; Children and Young People's Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT United Kingdom.

View Article and Find Full Text PDF
September 2020

Author Correction: The landscape of genomic alterations across childhood cancers.

Nature 2018 07;559(7714):E10

Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.

View Article and Find Full Text PDF
July 2018

The landscape of genomic alterations across childhood cancers.

Nature 2018 03 28;555(7696):321-327. Epub 2018 Feb 28.

Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.

View Article and Find Full Text PDF
March 2018

Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

Clin Cancer Res 2017 Jun;23(12):e62-e67

Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF
June 2017

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

Eur J Cancer 2017 04 17;75:63-72. Epub 2017 Feb 17.

Department of Translational Medicine, Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address:

View Article and Find Full Text PDF
April 2017

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells.

PLoS One 2015 30;10(12):e0145744. Epub 2015 Dec 30.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

View Article and Find Full Text PDF
June 2016

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.

Haematologica 2015 Apr 5;100(4):e132-6. Epub 2014 Dec 5.

Department of Pediatric Oncology/Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam Individualized Therapies for Children with Cancer Study Group Dutch Childhood Oncology Group, The Hague, The Netherlands

View Article and Find Full Text PDF
April 2015

Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.

J Mol Diagn 2015 Jan 24;17(1):43-52. Epub 2014 Oct 24.

Landsteiner Laboratory, Department of Pediatric Oncology, Emma Children's Hospital, Academical Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:

View Article and Find Full Text PDF
January 2015

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.

J Pharm Biomed Anal 2014 Apr 21;92:144-8. Epub 2014 Jan 21.

Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands. Electronic address:

View Article and Find Full Text PDF
April 2014

Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours.

Eur J Cancer 2014 Feb 6;50(3):628-37. Epub 2013 Dec 6.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands. Electronic address:

View Article and Find Full Text PDF
February 2014

Prevalence and clinical implications of chromothripsis in cancer genomes.

Curr Opin Oncol 2014 Jan;26(1):64-72

aDepartment of Medical Genetics, University Medical Center Utrecht, Utrecht bDepartment of Oncogenomics, Academic Medical Center, Amsterdam, The Netherlands.

View Article and Find Full Text PDF
January 2014

Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.

J Pharm Biomed Anal 2014 Jan 12;88:216-20. Epub 2013 Sep 12.

Amsterdam Medical Center, University of Amsterdam, Department of Oncogenomics, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article and Find Full Text PDF
January 2014

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Proc Natl Acad Sci U S A 2012 Nov 22;109(47):19190-5. Epub 2012 Oct 22.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

View Article and Find Full Text PDF
November 2012

Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.

BMC Cancer 2012 Jul 12;12:285. Epub 2012 Jul 12.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO box 22700, Amsterdam, AZ 1105, The Netherlands.

View Article and Find Full Text PDF
July 2012

Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth.

Eur J Cancer 2012 Nov 25;48(16):3093-103. Epub 2012 Feb 25.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article and Find Full Text PDF
November 2012

Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.

Eur J Cancer 2012 Mar 14;48(5):763-71. Epub 2011 Nov 14.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article and Find Full Text PDF
March 2012

Neuroblastoma therapy: what is in the pipeline?

Endocr Relat Cancer 2011 Dec 14;18(6):R213-31. Epub 2011 Nov 14.

Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University Medical Center, Gorlaeus Laboratories, The Netherlands.

View Article and Find Full Text PDF
December 2011

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe.

Endocr Relat Cancer 2011 Oct 27;18(6):657-68. Epub 2011 Oct 27.

Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO Box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article and Find Full Text PDF
October 2011

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Proc Natl Acad Sci U S A 2009 Aug 12;106(31):12968-73. Epub 2009 Jun 12.

Department of Human Genetics, Academic Medical Center, Department of Pediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam, Meibergdreef 15, PO box 22700, 1105 AZ Amsterdam, The Netherlands.

View Article and Find Full Text PDF
August 2009

Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma.

Cancer Res 2008 Apr;68(8):2599-609

Department of Human Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

View Article and Find Full Text PDF
April 2008

Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma.

Genes Chromosomes Cancer 2003 Mar;36(3):242-9

Department of Human Genetics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.

View Article and Find Full Text PDF
March 2003